Lymphocyte response to autologous tumor antigen(s) and phytohemagglutinin in ovarian cancer patients

Lymphocyte reactivity in patients with cancer of the oral cavity measured by sister chromatid differential staining

Lymphocyte reactivity in phytohemagglutinin-stimulated peripheral lymphocyte cultures from 22 patients with squamous cell carcinoma of the oral cavity and 29 age- and sex-matched controls was measured by the bromodeoxyuridine-Giemsa method for demonstrating sister chromatid differential staining. One hundred metaphases from each donor were counted, and the proportions of cells in the first, second, and third cycles were scored to estimate the in vitro mitogen responsiveness and cell division rates of the lymphocytes. The in vitro reactivity of peripheral lymphocytes of cancer patients was impaired in comparison with that of the controls, and the degree of reactivity of lymphocytes in cancer patients was not related to the size (greatest diameter) of the primary tumor. Results are discussed in relation to previously existing data.

Occurrence of a thermostable antigen of ovarian carcinoma in normal tissues and secretions

Thermostable antigen (TA) occurs in ovarian carcinoma and in certain specialized tissues. High titers of TA were found in nineteen of twenty endocervical extracts but not in myometrium, endometrium, or exocervix. TA was present in all of sixteen cervical mucus samples. Antibodies to perchloric acid extract of bronchus showed cross-reaticity with TA from ovarian carcinoma and cervix. Immunofluorescence with frozen sections revealed TA to be present in the columnar epithelium of ovarian neoplasms, and endocervical glands, in bronchial seromucous glands and in hepatic bile canaliculi. Immunofluorescence and immunodiffusion were used to test for cancer patient antibodies against TA. All sera tested negative. An immunofluorescence inhibition test for circulating TA also tested negative in sera of ovarian and cervical cancer patients.

Ovarian cancer: a solid tumor with evidence of normal cellular immune function but abnormal B cell function

Immunologic assays of B and T lymphocyte function were performed on 21 patients with epithelial ovarian cancer prior to either chemotherapy or radiotherapy. The results were compared to similar studies on 12 age-matched normal women. The total peripheral blood lymphocyte counts, proportion of E rosette positive cells, stimulation of T cells by phytohemagglutinin and concanavalin A, recall skin tests, and the ability to have a primary delayed hypersensitivity response to keyhold limpet hemocyanin did not differ between patients and controls. However, patients with ovarian cancer had statistically significant reduction in surface immunoglobulin positive cells, proliferative response to pokeweed mitogen and primary antibody response to keyhole limpet hemocyanin. In contrast to results in patients with other solid tumors, these data indicate that untreated patients with ovarian cancer have evidence of normal cellular immune function but abnormal B cell function.

Tumour associated immunity and immunocompetence in ovarian cancer

Cell-free extracts of autologous ovarian cancer cells evoked a delayed hypersensitivity response (DHR) in skin in four out of six patients in remission from disease and none of seven patients in relapse. These initial results appear to be consistent with in vitro blastogenic assay using the same autologous extracts. To assess whether diminished tumour-associated immunity was due to impaired cell-mediated immunocompetence, blastogenic responses to purified protein derivative of tuberculin (PPD), a secondary recall antigen, and phytohaemagglutinin (PHA) were assessed. Impaired responses to PHA were seen in the relapse group of patients, but responses to PPD did not appear to be impaired in this group.